This site is intended for healthcare professionals

ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Doxorubicin HCl
Bladder, kidney, and other urologic cancers
Bone and connective tissue cancer
Breast cancer
CNS cancers
Colorectal and other GI cancers
Gynecologic cancers
Leukemias, lymphomas, and other hematologic cancers
Pancreatic, thyroid, and other endocrine cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Doxorubicin HCl Rx

Generic Name and Formulations:
Doxorubicin HCl 10mg/vial, 20mg/vial, 50mg/vial; pwd for IV inj after reconstitution; contains lactose.

Company:
Various generic manufacturers

Therapeutic Use:

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, bladder carcinoma, Wilms' tumor).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, soft tissue and bone sarcomas).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, breast carcinoma). Adjunct in breast cancer after resection.

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, neuroblastoma).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, gastric carcinoma).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, ovarian carcinoma).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin's disease, malignant lymphoma).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, thyroid carcinoma).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Indications for Doxorubicin HCl:

Disseminated neoplasias (eg, bronchogenic carcinoma).

Adults and Children:

Monotherapy: usually 60–75mg/m2 IV every 21 days. Combination therapy: usually 40–60mg/m2 IV every 21 to 28 days. Hyperbilirubinemia, inadequate bone marrow reserves: reduce dose.

Contraindications:

Severe myelosuppression (baseline neutrophils <1500cells/mm3) or severe hepatic impairment. Cardiac disease (eg, severe myocardial insufficiency, arrhythmias). Recent MI. Previous treatment with max cumulative doses of anthracyclines, anthracenediones.

Warnings/Precautions:

Pre-existing heart disease or risk thereof. Obtain baseline CBC, bilirubin, AST, creatinine, LVEF. Hepatic dysfunction. Monitor cardiac function (LVEF, ECG echocardiogram), hepatic function, CBC, uric acid levels. Avoid extravasation. Children (cardiotoxicity, impaired myocardial growth). Elderly. Pregnancy (Cat.D; use adequate contraception). Nursing mothers: not recommended.

Interactions:

See Contraindications. Mediastinal irradiation, cyclophosphamide, calcium channel blockers, other anthracyclines increase risk of cardiac toxicity; limit lifetime dose to 400mg/m2. Necrotizing colitis with cytarabine. May increase toxicity of cyclophosphamide, mercaptopurine. May reduce serum digoxin levels. Doxorubicin toxicity increased with high-dose IV progesterone, cyclosporine, streptozocin, and if given after paclitaxel infusion (give doxorubicin dose first). Elimination increased by phenobarbital. May decrease phenytoin levels. Recall pneumonitis with actinomycin and radiation in children.

See Also:

Doxorubicin HCl Solution

Pharmacological Class:

Anthracycline.

Adverse Reactions:

Local necrosis if extravasation occurs, myocardial toxicity (immediate or delayed), arrhythmias, leukemia, myelosuppression, hyperuricemia, urine discoloration, alopecia, hyperpigmentation, severe GI upset/ulceration, phlebosclerosis, facial flushing, fever, urticaria, peripheral neuropathy, anaphylaxis.

How Supplied:

Contact supplier.

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.


Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Fever in adults - red flag symptomsExternal web site

Fever in adults can have potentially serious causes, ranging from sepsis to malignancy. Dr Pipin Singh...

0.50 Credits
Red flags

Bone pain - red flag symptomsExternal web site

In this article Dr Pipin Singh advises on how to identify red flags in patients presenting with bone...

0.50 Credits
Red flags

Pregnancy - red flag symptomsExternal web site

Dr Matthew West covers the red flags to look out for in pregnancy, including back pain, bleeding, headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Bronchiectasis: clinical reviewExternal web site

This article, updated in 2016 by Dr Anthony De Soyza, advises on causes, investigations and managing...

1.50 Credits
Clinical Review

Brugada syndrome: clinical reviewExternal web site

Dr Keith Barnard discusses the aetiology and symptoms of Brugada syndrome. Key learning points for GPs...

1.50 Credits
Clinical Review

Measles: clinical reviewExternal web site

Dr Kirsty Le Doare and Dr Nuria Martinez-Alier describe the signs and symptoms of measles and outline...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »